The North America Herpes Simplex Virus Treatment Market would witness market growth of 1.8% CAGR during the forecast period (2022-2028).
HSV-1 is mostly spread through contact with surfaces in or near the mouth, saliva, or sores that have the virus present. Less frequently, HSV-1 can spread from the mouth to the genital region and produce genital herpes. The danger of transmission is most serious when there are open sores, whether on the skin or in the mouth. HSV-1-positive individuals are not in danger of reinfection, but such individuals are still at risk of contracting HSV-2. HSV-2 is primarily spread during intercourse by contact with the anal or genital surfaces, skin, lesions, or fluids of an infected person.
HSV-2 can spread even if the skin seems normal and frequently does so without causing any symptoms. Neonatal herpes (HSV-1 & HSV-2) can, in extremely rare cases, be passed from mother to infant during birth. Currently, several herpes simplex virus control treatments are available in the market, like vaccines, pills, etc. A vaccine called SB208141 that GSK created has just finished Phase III of clinical trials.
Research and development efforts to create and offer competent and effective preventive solutions as vaccine candidates are additionally propelling the market's expansion. Also, since there is no licensed vaccine or treatment for herpes on the market, there is a greater need to produce and manufacture novel products.
Due to the rising frequency of herpes simplex virus infections, the demand for its treatment is rising in North America. Analytic Characterization of the Herpes Simplex Virus Type 2 Epidemic in the United States, 1950–2050, published in the Open Forum Infectious Diseases Journal in April 2021, claimed that over a century, the epidemic had changed significantly, having the greatest impact on people between the ages of 15 and 34. Moreover, in addition to the 47 million HSV illnesses that affected many people in 2020, there will be a high incidence during the following three decades, with more than 600,000 new infections arising each year. Therefore, the region's market is anticipated to develop due to the rising number of HSV infections.
The US market dominated the North America Herpes Simplex Virus Treatment Market by Country in 2021, and would continue to be a dominant market till 2028; thereby, achieving a market value of $532.3 Million by 2028. The Canada market is poised to grow at a CAGR of 3.8% during (2022 - 2028). Additionally, The Mexico market would witness a CAGR of 3.5% during (2022 - 2028).
Based on Drug Type, the market is segmented into Valacyclovir, Acyclovir, and Famciclovir. Based on Type, the market is segmented into Herpes simplex virus-1 Infection, and Herpes simplex virus-2 Infection. Based on Distribution Channel, the market is segmented into Drug Store & Retail Pharmacies, Hospital Pharmacies, and Online Pharmacies. Based on countries, the market is segmented into U.S., Mexico, Canada, and Rest of North America.
Free Valuable Insights: The Global Herpes Simplex Virus Treatment Market is Predict to reach $2.1 Billion by 2028, at a CAGR of 3%
The market research report covers the analysis of key stake holders of the market. Key companies profiled in the report include Abbott Laboratories, Pfizer, Inc., Amneal Pharmaceuticals, Inc., GlaxoSmithKline PLC, Teva Pharmaceuticals Industries Ltd., Glenmark Pharmaceuticals Limited, Fresenius SE & Co. KGaA, Novartis AG, Viatris, Inc., and Emcure Pharmaceuticals Limited.
By Drug Type
By Type
By Distribution Channel
By Country
Our team of dedicated experts can provide you with attractive expansion opportunities for your business.
Unique Offerings 